Prior to joining Lilly Ventures in 2009, he had over 24 years of operational experience in the pharmaceutical, biotechnology, and diagnostic businesses.   Dr. Shanafelt serves as a director on the boards of Aeglea Biotherapeutics (AGLE), Aileron Therapeutics (ALRN), Protagonist Therapeutics (PTGX), Surface Oncology (SURF), and Symic Bio.  He is a Kauffman Fellow (Class 14).
He received his B.S. Degree in Chemistry and Physics from Pacific Lutheran University and his Ph.D. in Chemistry from the University of California, Berkeley, and completed his postdoctoral work at DNAX Research Institute.